Clinical Trials Using Eltrombopag Olamine
Clinical trials are research studies that involve people. The clinical trials on this list are studying Eltrombopag Olamine. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Lenalidomide and Eltrombopag Olamine in Treating Patients with Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome
This phase II trial studies how well lenalidomide and eltrombopag olamine works in treating patients with symptomatic anemia in low or intermediate myelodysplastic syndrome. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Eltrombopag olamine may increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving lenalidomide and eltrombopag olamine may be an effective treatment for myelodysplastic syndrome.
Location: 3 locations
Eltrombopag Olamine and Filgrastim in Mobilizing Stem Cells in Patients with Multiple Myeloma Undergoing Peripheral Blood Stem Cell Transplant
This pilot clinical trial studies the best dose of eltrombopag olamine when given together with filgrastim in mobilizing stem cells in patients with multiple myeloma undergoing peripheral blood stem cell transplant. Eltrombopag olamine may increase production of platelets. Giving colony-stimulating factors, such as filgrastim helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored. Giving eltrombopag olamine together with filgrastim may improve the stem cell collection available for peripheral blood stem cell transplant in patients with multiple myeloma.
Location: 2 locations
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Relapsed Multiple Myeloma Undergoing Chemotherapy
This phase II clinical trial studies how well eltrombopag olamine works in treating thrombocytopenia in patients with relapsed multiple myeloma undergoing chemotherapy. Eltrombopag olamine may increase the number of platelets in patients with relapsed multiple myeloma undergoing chemotherapy.
Location: 4 locations
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
This phase II trial studies how well eltrombopag olamine works in improving the recovery of platelet counts in older patients with acute myeloid leukemia undergoing induction (the first treatment given for a disease) chemotherapy. Platelet counts recover more slowly in older patients, leading to risk of complications and the delay of post-remission therapy. Eltrombopag olamine may cause the body to make platelets after chemotherapy.
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant
This phase II trial studies how well eltrombopag olamine works in increasing platelet counts in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the immune system recover from blood or bone marrow transplant.
Location: M D Anderson Cancer Center, Houston, Texas